UnitedHealth Group Inc (UNH) Q1 2025 Earnings Call Highlights

 

• Adjusted Earnings Per Share Outlook: Revised to $26 to $26.50 for the year.

• Consolidated Revenue Outlook: Affirmed at $450 billion to $455 billion.

• Medical Care Ratio: Expected to be 87.5% plus or minus 50 basis points.

• Optum Health Revenue Outlook: $106 billion to $107 billion.

• Optum Health Operating Earnings: $6.2 billion to $6.4 billion.

• UnitedHealthcare Operating Earnings Outlook: $16 billion to $16.5 billion.

• Medicare Advantage Membership Growth: On pace to serve an additional 800,000 people this year.

• Optum Health Value-Based Care Patients: On track to add 650,000 net new patients.

• Optum Rx Revenue Growth: 14% increase, exceeding $35 billion for the quarter.

• Optum Rx Script Growth: 3% increase due to customer retention and new wins.

Release Date: April 17, 2025

Positive Points

• UnitedHealth Group Inc (NYSE:UNH) is experiencing strong growth across its businesses, with plans to serve an additional 800,000 people in Medicare Advantage this year.

• Optum Health is on track to add 650,000 net new patients to value-based care arrangements, indicating robust expansion in this segment.

• Optum Rx is experiencing a strong selling season with new wins and high retention of long-term customers, highlighting its role in reducing drug prices for consumers.

• The company has introduced several initiatives to improve consumer experience, including AI-driven call routing and the removal of prior authorizations on certain drugs.

• UnitedHealth Group Inc (NYSE:UNH) is seeing increased digital engagement among senior members, leading to higher wellness visits and better health management.

Negative Points

• UnitedHealth Group Inc (NYSE:UNH) revised its adjusted earnings per share outlook for the year to $26 to $26.50, reflecting performance challenges.

• The company is facing increased care activity in its Medicare Advantage business, with utilization trends doubling compared to expectations.

• Unanticipated changes in Optum Medicare membership profiles are impacting 2025 revenue, with reimbursement levels below expectations.

• The transition to the new CMS risk model is proving more complex than anticipated, affecting operational execution.

• UnitedHealth Group Inc (NYSE:UNH) is dealing with the effects of Medicare funding cuts, which have led to higher premiums and altered member behavior.

Q & A Highlights

Q: Can you share the Medicare Advantage cost trend estimate for 2025 and how it compares to 2024? A: Andrew Witty, CEO, explained that the company anticipated care levels consistent with 2024. However, they observed a twofold increase in care activity in Q1 2025, particularly in physician and outpatient services. Timothy John Noel, CEO of UnitedHealthcare Medicare & Retirement, added that they expect this trend to persist throughout 2025 and into 2026, shaping their pricing assumptions.

Q: How does the higher incidence of primary care visits relate to Optum Health's performance, and why is value-based care still a strategic focus? A: Andrew Witty, CEO, noted that Optum Health and UnitedHealthcare operate different models. Amar Desai, CEO of Optum Health, highlighted that new value-based patients were less engaged by prior plans, impacting performance. Heather Bresch, an unidentified company representative, emphasized that value-based care offsets trends by engaging patients early, reducing emergency visits, and improving outcomes, supporting long-term growth.

Q: What are the key elements to return to UnitedHealth's long-term growth rate? A: Andrew Witty, CEO, expressed confidence in returning to the long-term growth rate, citing improved 2026 rates and the end of the transition period of absorbing pricing pressure. He emphasized addressing second-order effects seen in 2025 and fixing issues to deliver stronger performance in 2026.

Q: What is UnitedHealth's stance on PBM reform and Medicaid funding cuts? A: Patrick Conway, CEO of Optum Health, highlighted UnitedHealth's transparency and affordability initiatives, including commercial rebate pass-through and cost-based reimbursement for pharmacies. Krista Nelson, CEO of UnitedHealthcare Community & State, emphasized their broad footprint and confidence in supporting states through changes, focusing on member health and coverage access.

Q: How is UnitedHealth addressing the impact of tariffs on pharmaceuticals? A: Andrew Witty, CEO, stated that while the situation is dynamic, UnitedHealth feels well-positioned due to price protection mechanisms in contracts and legislation limiting manufacturers' ability to pass price increases. They are monitoring developments and will adjust bids thoughtfully.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

https://finance.yahoo.com/news/unitedhealth-group-inc-unh-q1-070208857.html

Toyota May Add U.S. Production of RAV4 in Response to Tariffs

 Toyota is considering producing the next version of its top-selling RAV4 SUV in the United States, three people familiar with the matter said, becoming the latest automaker to rethink supply chains to lessen the hit from U.S. tariffs on imported vehicles.

Toyota makes the current version of the popular SUV in Kentucky, Canada and Japan. It originally planned to export the new RAV4 to the United States from Canada and Japan but it is now also considering production in Kentucky as one option, given that demand for the car looks likely to outstrip supply, according to the people, all of whom declined to be identified because the information is not public.

Adding supply from the United States would also lessen the impact for the Japanese automaker from President Donald Trump's 25% tariffs on imported cars and avoid potentially higher costs in cases of fluctuations in the volatile yen currency, two of the people said.

Toyota is set to unveil an overhauled 2026 RAV4 - its first redesign since the fifth-generation 2019 model - later this year and will then gradually introduce it in different markets around the world, one of the people said. It has yet to announce the exact timing of the U.S. roll-out.

Toyota has yet to finalise its production plans, the people said. Any production changes cannot be implemented quickly and require long-term planning, one of them said, due to the time-consuming and capital-intensive work involved in retooling manufacturing facilities and adjusting supply chains.

If the automaker goes ahead with the Kentucky plan, it would probably start production there in 2027, one of the people said. Regardless of the outcome with Kentucky, Toyota's overall vehicle output in Canada is likely to be maintained, the people said.

Toyota said in a statement to Reuters that it continually studied ways to improve its manufacturing to best serve customers and provide stable employment for employees.

"We have nothing to announce at this time and will not comment on speculation," it said when asked about plans to produce the new version of the RAV4 in Kentucky.

The RAV4 was the best-selling vehicle in the U.S. last year, knocking Ford's F-150 pickup truck off the top spot it held for years, according to market research firm JATO Dynamics.

Toyota sold more than 475,000 RAV4s in the U.S. last year, accounting for a fifth of its total vehicle sales there.

It was not immediately clear how many of the new RAV4 the carmaker would produce in the United States. It has 11 plants in the U.S., including auto-parts plants, and produced almost 1.3 million vehicles there in 2024, equivalent to more than half of its 2.3 million U.S. car sales.

Toyota said this month it will continue to run its operations as normal and focus on bringing down fixed costs, stopping short of taking more drastic steps such as raising vehicle prices in response to the tariffs.

Global automakers, including U.S.-based ones that produce cars in other countries, face the spectre of potentially higher costs from the 25% levy on imported cars introduced this month.

Nissan plans to reduce Japanese production of its top-selling U.S. model by 13,000 vehicles over the three months to July, Reuters reported on Tuesday. Honda plans to make its next-generation Civic hybrid in the U.S. state of Indiana rather than in Mexico to avoid potential tariffs, Reuters has reported.

Trump said on Monday he was considering modifying the auto levy because manufacturers "need a little bit of time".

Japanese automakers have been building up U.S. production for decades. Toyota says its total investment in the U.S. over the years has reached almost $50 billion.

Tokyo's top trade negotiator, Ryosei Akazawa, met with Trump and U.S. officials in Washington to discuss tariffs on Wednesday. Trump said there was "big progress" in the talks, after he made the surprise move to negotiate directly with the Japanese trade delegation.

https://www.aol.com/news/exclusive-toyota-weighs-adding-us-064500085.html

Chinese Satellite Imaging Firm Helping Houthis Target US Warships

 Washington is now accusing China of getting in bed with the Iran-backed Shia Houthis of Yemen, who have long waged a war against Red Sea shipping, including attacks on US warships and Israel.

The US State Department on Thursday issued allegations centered on Chinese firm, Chang Guang Satellite Technology, saying it is directly supporting attacks by Houthi fighters against American interests. This firm is well-known to be close to the CCP government, and is already under Western sanctions.

"We can confirm the reporting that Chang Guang Satellite Technology Company Limited (CGSTL) is directly supporting Iran-backed Houthi terrorist attacks on U.S. interests," State Department spokesperson Tammy Bruce told a press briefing.

The statement was issued in the wake of a Financial Times report which said the firm is supplying the Houthis with satellite imagery used in targeting. 

"The United States has raised our concerns privately numerous times to the Chinese government on Chang Guang Satellite Technology Co Ltd’s role in supporting the Houthis in order to get Beijing to take action," a US officials was quoted in the report as saying. But these warnings were reportedly "ignored".

CGSTL has long been described as close to the Chinese government, and has been a central firm in the country's military-civil fusion program, which requires private sector companies to provide assistance to the government when called upon. The Chinese Embassy in Washington has denied any awareness of these new allegations concerning support to the Houthis. Interestingly, public company documents present the firm's purpose as providing "earthquake services". 

And the state connections are clear...

According to background on the company via FT:

The Chinese company was established in 2014 as a joint venture between the provincial government in Jilin and a branch of the Chinese Academy of Sciences in Changchun, the province’s capital.

“Chang Guang is one of a handful of ‘ostensibly’ commercial Chinese satellite companies that are in fact deeply embedded in the military-civil fusion ecosystem, supplying global surveillance capabilities to both civilian and military customers,” said James Mulvenon, an expert on the Chinese military and intelligence services at Pamir Consulting.

It previously came under US sanctions during 2023 in connection with the Ukraine war, having been accused of giving high-resolution satellite imagery to Wagner Group, Russia's most well-known and controversial mercenary firm.

The FT report indicates that CGSTL had Chang Guang 100 satellites in orbit as of last year, and there are ambitious plans achieve 300 circling the earth by the end of 2025, which would allow for snapshots of any location on the planet each ten minutes.

If it does have a role in Yemen, this will further damage already severely strained US-China relations mid the tariff war, given the Houthis have frequently directly targeted US warships, including the carrier USS Harry S. Truman with drone and missile attacks. The USS Carl Vison carrier is about to joint the Truman in patrolling regional waters, also as tensions heat up with Iran.

https://www.zerohedge.com/geopolitical/chinese-satellite-imaging-firm-helping-houthis-target-us-warships

UnitedHealth to enter mediation with DOJ over Amedisys deal

 

• UnitedHealth and Amedisys are heading to mediation with the Department of Justice over the DOJ’s bid to block their $3.3 billion merger over anticompetitive concerns.
• Late last week, Judge Susan Gauvey of Maryland’s district court scheduled August 18 for a mediation conference, wherein UnitedHealth, Amedisys and antitrust regulators will have a magistrate judge’s help in hashing out a solution to the DOJ’s opposition.
• The DOJ filed its lawsuit in November arguing UnitedHealth’s buy of Amedisys, one of the largest home health and hospice providers in the U.S., would raise prices for consumers in more than 20 states. Maryland, Illinois, New Jersey and New York also joined the DOJ’s complaint.

UnitedHealth’s health services division Optum first announced plans to buy Amedisys in summer 2023 after a bidding war over the Louisiana-based home health and hospice provider. Amedisys shareholders approved the deal later that year.

However, the merger has been held up by antitrust regulators, who say UnitedHealth’s ownership of LHC Group, a rival to Amedisys that UnitedHealth acquired for $5.4 billion in 2023, is cause for concern.

If the transaction goes through, Optum will control 30% or more of the home health or hospice markets in eight states, the DOJ said in its complaint. The deal will also add 500 care sites to Optum’s home health and hospice portfolio and extend its reach into five additional states, harming patients and providers by eliminating competition, according to the DOJ.

UnitedHealth and Amedisys, which deny that their merger would have anticompetitive effects, have offered plans to divest businesses to ameliorate the DOJ’s concerns.

Most recently, UnitedHealth and Amedisys offered to sell more than 120 home health and hospice facilities, according to a court filing in February. If the sales are approved, UnitedHealth would only operate 10% of home health and 4% of hospice services in the U.S.

Still, the offers have not proved sufficient for the DOJ, which has grown increasingly concerned about the size and influence of UnitedHealth — a company that operates one of the largest insurers in the nation, a major pharmacy benefit manager and a healthcare technology company, while employing thousands of physicians.

The DOJ is reportedly investigating the conglomerate for its potential anticompetitive effects, including the relationship between Optum and its insurer UnitedHealthcare. Meanwhile, the Federal Trade Commission is suing UnitedHealth’s PBM, Optum Rx, along with other PBMs for allegedly driving up the price of insulin.

https://www.healthcaredive.com/news/unitedhealth-amedisys-doj-mediation/745386/

New research kindles excitement around stem cell therapies for Parkinson’s

 The most effective drug for Parkinson’s disease hasn’t changed in 50 years. But fresh research published in one of the country’s top scientific journals is helping build the case for a more cutting-edge approach that uses stem cells to restore important brain functions.

The second most common neurodegenerative illness, Parkinson’s is caused by the loss of certain nerve cells. These cells produce a chemical messenger, dopamine, that plays a crucial role regulating movement. Since the 1970s, a drug called levodopa, which the body converts into dopamine, has been the mainstay treatment for combating the tremors, slowness, stiffness and balance issues that come with Parkinson’s.

Levodopa doesn’t stop the disease, however, so scientists have spent decades trying to find a more permanent fix. The latest development in that search comes from two clinical trials testing stem cell-derived therapies transplanted into the brains of Parkinson’s patients.

The first of those trials, conducted at the Kyoto University Hospital in Japan, evaluated seven people who received what are essentially blank slate cells that can turn into dopamine-producing neurons. These cells were created using a technology pioneered at Kyoto University, where roughly 20 years ago, scientists discovered how to reset some adult human cells to act like stem cells.

The study’s main focus was safety. Results, published Wednesday in Nature, show no serious adverse events were reported, though researchers did identify 73 mild to moderate events. Importantly, there was no evidence the introduced cells started growing in an unchecked, tumor-like fashion — a major concern with stem cell implants.

The study also explored whether this therapy had any effect on patients’ disease. Two years post-treatment, the six participants who were evaluable had gotten better on a scale clinicians use to measure the severity of Parkinson’s motor symptoms. Researchers looked at what’s known as “on” time, when medications are adequately controlling these symptoms, as well as the opposite “off” time, and found scores improved an average of 36% and 20%, respectively.

Another test indicated that dopamine-producing cell activity had increased substantially. This was determined through a technique in which researchers strap a radioactive element to a molecule of levodopa and then use a PET scan to follow its path through the nervous system, somewhat like how a submarine tracks objects on a sonar display.

The second trial took place at sites throughout the U.S. and Canada, and employed a different kind of stem cell that comes from human embryos. It enrolled a total of 12 participants and followed them for a year post-transplant.

Similar to the Japan study, there were no deaths, serious adverse events or tumor-like tissue growth related to the introduced cells. Trial runners did report two serious events overall. One participant was hospitalized with COVID-19, while another had a seizure that was attributed to the surgical procedure.

The trial also saw improvements in “off” scores on that disease severity scale and positive results from the radioactive levodopa test.

The cell therapy tested, called bemdaneprocel, is being developed by Bayer subsidiary BlueRock Therapeutics, which back in August 2023 announced some of the data published Tuesday. The company expects to start a Phase 3 trial before the end of June.

Hideyuki Okano, a stem-cell scientist at Keio University in Tokyo, argues more research is needed to confirm these types of cell therapies are effective against Parkinson’s.

Still, in an accompanying Nature editorial, he called the new trial results “encouraging” because they suggest treating Parkinson’s patients with donor cell transplants is likely safe. That both trials “proved to be safe, and hinted at possible efficacy, is an important step towards the establishment of this cell therapy for Parkinson’s disease in wider society,” he wrote.

Cell therapy for Parkinson’s isn’t a new idea. In 1989, a team led by neuroscientist Olle Lindvall performed the first cell transplantations for Parkinson’s patients. While the landmark study didn’t show a major therapeutic benefit, a few interesting signals encouraged the research community to keep exploring.

One ethical concern from that trial was that it used a relatively large amount of tissue derived from aborted fetuses. In the decades since, Parkinson’s and cell biology experts have made significant progress identifying other, less controversial sources of stem cells that can be scaled more easily.

A milestone of that work came in 2020, when the technique invented at Kyoto University was used to turn a Parkinson’s patient’s own skin cells into the early stages of dopamine-producing neurons, which were then implanted into his brain.

According to Okano, as of December, there were 115 clinical trials testing 83 products derived from “pluripotent” stem cells. And among those targeting central nervous system disorders, the ones for Parkinson’s disease are at a more advanced stage of development.

Further behind Bayer and BlueRock, Aspen Neuroscience, a San Diego-based biotechnology company, has a Parkinson’s therapy derived from patients’ own cells currently in early-stage human testing.

https://www.biopharmadive.com/news/parkinsons-stem-cell-therapy-nature-studies/745519/

Trump Signs Order To Help States Import Low-Cost Medications

 by Lawrence Wilson via The Epoch Times (emphasis ours),

President Donald Trump signed an executive order on April 15 that directs a wide range of actions to lower the cost of prescription medications, including through the importation of prescription drugs from Canada by the states.

States have been authorized since 2020 to import certain drugs from Canada—where they are often available at a lower price—under section 804 of the Food, Drug and Cosmetics Act. However, approval from the Food and Drug Administration is required, and that process is complex.

Florida is the only state now authorized to import drugs from Canada, and the approval process took more than three years.

Trump’s order instructs the Food and Drug Administration to improve the process and encourages states to apply for authorization to import medications.

An analysis by health research group KFF found that per-capita spending on prescriptions was 42 percent higher in the United States than in Canada.

Lowering Prices

Three items in the executive order aim at lowering the cost of drugs already available in the United States.

The first such action is to revisit the Medicare drug negotiation program, which was authorized by the Inflation Reduction Act.

This program allows Medicare to negotiate with drug companies to reduce the cost of brand-name drugs approved for Medicare Part B and Part D beneficiaries.

The initial round of lower prices involving 10 prescription medications will take effect on Jan. 1, 2026. A second round of 15 drugs will be available for Medicare beneficiaries at a reduced price in 2027.

A White House official told reporters that the Trump administration would improve the program and make it more transparent.

A second price-lowering action aims to make Medicare’s payment for prescription drugs commensurate with the supplier’s cost. Currently, Medicare pays as much as 35 percent over the actual cost of some medications.

A third provision for lowering prices directs that steps be taken to ensure that Medicare pays a comparable price for prescription drugs regardless of where they are dispensed.

Currently, Medicare may pay up to 60 percent more for a drug dispensed at an outpatient clinic than for the same medication dispensed at a doctor’s office, which creates an incentive for providers to drive traffic to the higher-paying location.

A fourth action item directs Dr. Mehmet Oz, administrator of the Centers for Medicare and Medicaid Services, to further reduce the price of insulin.

Currently, the negotiated price is $35. A White House official told reporters that, based on the new order, low-income and uninsured patients may be able to receive insulin for as little as 3 cents per vial, plus an administrative fee. Injectable epinephrine may be available for as little as $15 per auto-injector.

This order will achieve that by ensuring that all discounts on insulin and epinephrine that the government offers to health care providers are passed on to consumers.

The Drug Pipeline

Other provisions of Trump’s order aim to lower costs by improving the drug development and approval process.

First, the order directs the Food and Drug Administration to streamline the approval process for generic and biosimilar medications. That could reduce the price of medication for some patients by as much as 80 percent.

Currently, there is a backlog of generic and biosimilar medications awaiting approval, according to the White House.

Second, Trump’s order directs Health and Human Services Secretary Robert F. Kennedy Jr. to work with Congress to address what the administration sees as an imbalance in the emphasis placed on the development of some highly expensive drugs.

Small-molecule medications are produced from chemicals, are less costly, and can treat a wide variety of ailments. Ibuprofen is an example of a small-molecule medication.

Large-molecule medications are derived from living organisms, are more costly to produce, and are delivered by infusion. Gene-based therapies, immunotherapies, and hormonal regulators are examples of large-molecule medications.

The current system encourages companies to invest in developing the more expensive large-molecule treatments over less costly alternatives, according to the White House.

No timeline for implementing that legislative solution was announced.

One element of Trump’s order cracks down on the practices of some brokers in the prescription drug supply chain.

The order directs the Department of Labor to set rules concerning the disclosure of broker fees for prescription drugs.

In some cases, employers hire a broker to negotiate prescription drug fees on behalf of their employees, but the broker may act against the employer’s best interest by accepting fees from the pharmacy benefit manager that it recommends, according to a White House official.

Provisions supporting this rule-making are included in the Consolidated Appropriations Act but have not been fully enforced, according to the White House.

https://www.zerohedge.com/political/trump-signs-order-help-states-import-low-cost-medications